Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D46RKC
|
|||
| Drug Name |
Fitusiran
|
|||
| Synonyms |
ALN-AT3SC
Click to Show/Hide
|
|||
| Drug Type |
Small interfering RNA
|
|||
| Indication | Hemophilia [ICD-11: 3B10.0; ICD-10: D66-D68; ICD-9: 286] | Phase 3 | [1] | |
| Company |
Sanofi
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | SERPINC1 messenger RNA (SERPINC1 mRNA) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03549871) A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis (ATLAS-PPX). U.S. National Institutes of Health. | |||
| REF 2 | Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy. N Engl J Med. 2017 Aug 31;377(9):819-828. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.